中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共24条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 期刊论文
BLOOD ADVANCES, 2023, 卷号: 7
作者:  Bachy, Emmanuel;  Savage, Kerry J.;  Huang, Huiqiang;  Kwong, Yok-Lam;  Gritti, Giuseppe;  Zhang, Qingyuan;  Liberati, Anna Marina;  Cao, Junning;  Yang, Haiyan;  Hao, Siguo;  Hu, Jianda;  Zhou, Keshu;  Petrini, Mario;  Russo, Filomena;  Zhang, Huilai;  Sang, Wei;  Ji, Jie;  Ferreri, Andres Jose Maria;  Damaj, Gandhi Laurent;  Liu, Hui;  Zhang, Wei;  Ke, Xiaoyan;  Ghiggi, Chiara;  Huang, Sha;  Li, Xiaotong;  Yao, Hui;  Paik, Jason;  Noveotny, William;  Zhou, Wenxiao;  Zhu, Hongji;  Zinzani, Pier Luigi
收藏  |  浏览/下载：29/0  |  提交时间：2023/11/10
The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study 期刊论文
CANCERS, 2022, 卷号: 14
作者:  Xie, Mingying;  Li, Na;  Xu, Xiaoling;  Xu, Yanjun;  Li, Hui;  Zhu, Liang;  Sheng, Jiamin;  Zhou, Zichao;  Fan, Yun
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/22
liver metastasis  non-small cell lung cancer  PD-L1  PD-1  PD-L1 inhibitor  CD8+T cell  
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study 期刊论文
GENES CHROMOSOMES & CANCER, 2022
作者:  Wang, Wenxian;  Gu, Xiaodong;  Si, Jinfei;  Pu, Xingxiang;  Wang, Liping;  Chen, Huafei;  Xu, Chunwei;  Zhang, Xiaoyan;  Yuan, Hongling;  Lou, Guangyuan;  Shao, Lan;  Zhang, Gu;  Song, Zhengbo
收藏  |  浏览/下载：55/0  |  提交时间：2022/05/16
BRAF mutation  immune checkpoint inhibitors  non-small cell lung cancer  PD-L1  targeted therapy  
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer 期刊论文
JOURNAL OF ONCOLOGY, 2022, 卷号: 2022
作者:  Li, Yue;  Li, Chong;  Jiang, Ya;  Han, Xue;  Liu, Sisi;  Xu, Xiuxiu;  Tang, Wanxiangfu;  Ou, Qiuxiang;  Bao, Hua;  Wu, Xue;  Shao, Yang;  Xing, Minyan;  Zhang, Yixiang;  Wang, Yuezhen
收藏  |  浏览/下载：39/0  |  提交时间：2022/12/23
Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy 期刊论文
ANNALS OF TRANSLATIONAL MEDICINE, 2022
作者:  Xu, Liwei;  Qi, Yajun;  Jiang, Youhua;  Ji, Yongling;  Zhao, Qiang;  Wu, Jie;  Lu, Weishan;  Wang, Yinjie;  Chen, Qixun;  Wang, Changchun
收藏  |  浏览/下载：73/0  |  提交时间：2022/05/05
Gut microbiome  esophageal squamous cell carcinoma (ESCC)  neoadjuvant therapy  immunotherapy  
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng;  Zou, Dehui;  Li, Wei;  Yang, Haiyan;  Liu, Ting;  Wang, Quanshun;  Lv, Fangfang;  Guo, Haiyi;  Zhao, Xia;  Wang, Dan;  Zhang, Pei;  Wang, Yidi;  Wang, Lei;  Liu, Tengfei;  Zhang, Yun;  Shen, Zhirong;  Huang, Jane;  Zhu, Jun
收藏  |  浏览/下载：47/0  |  提交时间：2022/05/05
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin
收藏  |  浏览/下载：46/0  |  提交时间：2022/05/16
Sarcoid-like reaction  immune checkpoint inhibitor  Toripalimab  PD-1  case report  
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao;  Yu, Haifeng;  Guo, Na;  Li, Cong;  Peng, Shuailing;  Dong, Xiaowu;  Yang, Haiyan;  Wu, Meijuan
收藏  |  浏览/下载：64/0  |  提交时间：2022/02/14
Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment  
A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer 期刊论文
FRONTIERS IN IMMUNOLOGY, 2021, 卷号: 12
作者:  Peng, Jie;  Zou, Dan;  Han, Lijie;  Yin, Zuomin;  Hu, Xiao
收藏  |  浏览/下载：53/0  |  提交时间：2022/02/14
non-small cell lung cancer  support vector machine  major pathological response  liquid immune profiling  neoadjuvant treatment  
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun;  Nishio, Makoto;  Li, Jiang;  Zhou, Yunfei;  Rhee, Joon Whan;  Duque, Sandra Chica;  Yu, Xinmin
收藏  |  浏览/下载：58/0  |  提交时间：2022/01/10